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Summary Of 297 patients with metastatic testicular and extragonadal germ cell tumours (GCT), bone
involvement was detected clinically in 3% (7/251) of those at first presentation and in 9% (4/46) of relapsed
cases. This difference was not statistically significant (95% confidence limits -2%; +14%). Concurrent
systemic metastases, commonly involving lung (7/11 cases) and para-aortic lymph nodes (6/11), were present
in all patients with bone disease. All affected patients had localized bone pain and lumbar spine was the most
frequent site involved (9/11). Spinal cord compression occurred in two patients while a third developed
progressive vertebral collapse after chemotherapy and required extensive surgical reconstruction. At median
follow-up of 4 years, survival among patients presenting with bone disease (6/7) was similar to overall
survival in the whole group (84%) and appeared better than in those with liver (18/26, 69%) or central
nervous system (6/9) metastases at presentation.
Back pain in metastatic germ cell tumours is often due to retroperitoneal lymphadenopathy but lumbar
spine osseus metastases must be recognized early if severe potential complications, such as spinal cord
compression, are to be avoided. In this series, bone metastases were not seen in the absence of widespread
systemic disease suggesting all solitary bony lesions in GCT patients should be biopsied.
Bone is an uncommon site for metastases from testicular and
extragonadal germ cell tumours (GCT) (Pugh, 1982). The
large study of Dixon & Moore (1953) described metastases
seen in 1,000 testicular GCT affecting United States service-
men to January 1948. Autopsy-proven bony metastases were
seen in 21% of GCT containing mainly embryonal
carcinoma and 36% of those with predominant teratoma but
not in other histologic types. Bones of the trunk were
involved most commonly. Mostofi (1973) reported 6,000
testicular tumours on the American Registry of Pathology
over 25 years and noted a similar distribution of osseus
metastases. These pathologic series largely predated the
considerable recent advances in treatment of GCT and in
methods for demonstrating bone metastases radiologically
during life. With optimal radiotherapeutic techniques in
seminoma, very high overall cure rates have been possible
for over 20 years (Ball et al., 1982; Duncan & Munro, 1987;
Hay et al., 1984). Isotope bone scans, computerized
tomography (CT) and, most recently, magnetic resonance
imaging (MRI) have provided much more sensitive means
for diagnosing bone involvement than plain radiographs.
Johnson et al. (1976) reported an autopsy series of
testicular GCT where 47% of bony metastases were seen
among seminoma patients, significantly more than in all
other histologic subtypes. Bredael et al. (1982) showed
similar results in another postmortem series. This apparent
change in metastatic pattern from the older series may reflect
radiotherapy-induced modification of seminoma natural
history with retroperitoneal disease controlled but late
recurrence occurring in other sites, including bone, and
leading to subsequent death. Now, long term remission and
cure in non-seminomatous GCT is common due to
widespread use of cisplatin-based combination chemotherapy
(Bosl et al., 1986; Logothetis et al., 1986; Newlands et al.,
1986; Williams et al., 1987). Such chemotherapy has also
proved effective first-line management for bulky metastatic
seminoma and as salvage treatment for seminoma patients
relapsing after radiotherapy (Loehrer et al., 1987; Stanton et
al., 1985).
Bone involvement at presentation with GCT is an adverse
prognostic feature equivalent to liver or central nervous
system (CNS) metastases according to most authors (Bosl et
al., 1986; Logothetis et al., 1986; Williams et al., 1987).
However, references to bone secondaries from testicular
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GCT in recent textbooks of Oncology or Urology are brief
(Barzell & Whitmore, 1979; Einhorn et al., 1985; Garnick et
al., 1982; Pugh, 1982) and only anecdotal reports of bony
metastases from testicular and extragonadal GCT exist
(Collis & Eckert, 1985; Gay et al., 1985; Hermann, 1986;
Martini et al., 1974; Richardson et al., 1981; Sagalowsky et
al., 1986), mostly referring to seminoma. The incidence of
clinically detectable osseous metastases, responsiveness of
such metastases to currently available chemotherapy, and
long term prognosis in patients with bone involvement from
GCT remain poorly defined. This paper analyses 10 years'
single institution experience with bone metastases from GCT
in an attempt to address these issues and describes some
unique management problems which arose in affected
patients.
Patients and methods
Records from 297 male patients treated for metastatic GCT
of testicular or extragonadal origin between 1977 and 1987
were examined. Most received first-line chemotherapy for
non-seminomatous GCT but some were referred for salvage
chemotherapy after relapse and others with advanced
seminoma were treated primarily using chemotherapy.
Histologic sub-types included seminoma, malignant teratoma
undifferentiated (MTU), malignant teratoma intermediate
(MTI), malignant teratoma trophoblastic (MTT), and
malignant teratoma differentiated (MTD) according to
British Testicular Tumour Panel Criteria (Pugh, 1976). All
patients underwent regular measurement of serum tumour
markers alpha foetoprotein (AFP) and human chorionic
gonadotrophin (hCG) as well as serum calcium and alkaline
phosphatase. Chemotherapy was administered according to
the POMB/ACE (cisplatin, vincristine, methotrexate,
bleomycin, actinomycin D, cyclophosphamide, etoposide)
protocol (Newlands et al., 1986) or a weekly salvage regimen
EP/OMB (etoposide 150mgm-2 intravenously (i.v.) plus
cisplatin 75mgm-2 i.v. alternating with vincristine 1 mgm-2
i.v., methotrexate 300mgm-2 i.v. over 12h and bleomycin
30mgi.v. over 48h).
Bone involvement was diagnosed on the basis of
symptoms, usually pain, plus bone destruction demonstrated
using one or more imaging technique including plain radio-
graphs, CT scan, isotope bone scan, and magnetic resonance
imaging (MRI). Bone biopsy for histologic confirmation was
performed in a majority of cases.
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Results
Osseus involvement was noted in 11 cases. Among patients
not treated previously, 7 of 251 (3%) had bone disease at
presentation and their characteristics are shown in Table I.
Most histologic subtypes of GCT were represented in the
group with bony involvement. Median follow-up for all non-
pretreated patients is 4 years (range one week to 10.8 years)
and survival among those with bone involvement (6/7, 86%)
was similar to the whole group (84%). By contrast, poorer
overall survival was seen among patients with liver
metastases at presentation (18/26, 69%) and those with CNS
disease at presentation (6/9, 67%). Four of 46 patients (9%)
developed bony metastases as part of systemic relapse of
their non-seminomatous GCT. Two of these have succumbed
despite further treatment.
Coincident metastatic disease elsewhere was noted in all
patients with bone involvement, commonly lung (7/11 cases)
and para-aortic lymph nodes (6/11). The predominant site of
bony involvement was lumbar spine (9/11). Other sites
affected were ribs (one case) and skull (two cases) but only
two patients had more than one bony site involved
concurrently. All patients with bone disease had localized
pain. One patient had spastic paraplegia from spinal cord
compression at diagnosis, one developed early cord
compression after commencing treatment, and a third
sustained this complication at relapse. Results of various
imaging methods were: plain radiographs showed local bone
destruction in 4 of 11 patients, CT scans were positive in 7
of 8 cases with appropriate images obtained, 4 of 6 bone
scans performed were positive, and MRI was diagnostic in
all three patients who had the investigation performed.
Histologic confirmation of osseus metastasis was obtained in
5 cases and changes compatible with necrotic GCT were seen
in a sixth patient who had lumbar vertebral biopsy taken at
post-chemotherapy retroperitoneal lymphadenectomy. Im-
provement in the bony changes was evident in two long term
survivors who had adequate serial images available. Serum
tumour markers were elevated in all but one patient with
bone metastases, AFP in 8 of 11 cases and hCG in 8 of 11
cases. The one exception had pure seminoma. Serum alkaline
phosphatase was elevated in 7 of 11 cases but raised serum
calcium was seen in only one patient. No clinically
unrecognized bone metastases were seen among 15 GCT
patients who came to autopsy during the period of this
study.
Three individual cases are worth highlighting:
Case I: A 39 year old man presented with multiple lumbar
Table I Characteristics of previously untreated GCT patients with
bony metastases
Bone No bone
involvement involvement
(n =7) (n =244)
AGE: median (yrs)
range (yrs)
HISTOLOGY:
(1) Seminoma
(2) MTU
(3) MTI
(4) MTT
(5) MTD
(6) Unknown
PRIMARY SITE:
(a) Testis
(b) Extragonadal
OTHER SITES OF DISEASE:
(i) Para-aortic
(ii) Lung
(iii) Liver
(iv) Mediastinum
(v) CNS
vertebral metastases, massive para-aortic lymphadenopathy, lung
metastases and mediastinal involvement from testicular MTU. He
was treated with POMB/ACE chemotherapy (Newlands et al., 1986)
and had a rapid response in the tumour but progressive vertebral
collapse occurred, threatening spinal cord compression (Figure 1).
Extensive surgical reconstruction of the lumbar spine was necessary
and tissue obtained at this procedure also revealed MTU. Three
months after ceasing the first-line therapy, in apparent complete
remission, he sustained an isolated CNS relapse. Owing to the
structural problem in the lumbar spine, he had not received CNS
prophylaxis with intrathecal methotrexate. The brain metastasis was
removed at craniotomy and an Ommaya reservoir inserted. Owing
to renal impairment following his prior chemotherapy, he was
treated with weekly chemotherapy with carboplatin, etoposide and
bleomycin, together with weekly injections of methotrexate in a dose
of 12.5mg into the Ommaya reservoir. He now remains disease-free
but needs a walking aid due to residual back problems rather than
sequelae of his CNS disease.
Case II: A 25 year old male originally presented with painful
testicular enlargement which was initially diagnosed as a hydrocoele.
While awaiting elective surgery he developed increasingly severe
lumbar back pain. Although radiographs were taken of the lumbar
spine, the partial collapse of L2 was not noted. Six weeks after
seeking medical attention for testicular swelling he developed dense
paraplegia due to spinal cord compression and was referred to the
Charing Cross Hospital. MRI scan demonstrated the pathology
clearly (Figure 2) and interestingly showed para-aortic lymphadeno-
pathy of modest proportions (2-3cm maximum diameter) at a lower
level than the bone lesion. Tissue obtained from the affected
vertebra at laminectomy revealed MTU identical to the testicular
histology which was obtained concurrently. He has now completed
POMB/ACE chemotherapy (Newlands et al., 1986), his tumour is in
remission and he has made a partial neurological recovery.
Case III: A 57 year old man presented with testicular seminoma
causing massive para-aortic lymphadenopathy (>10cm diameter)
and lytic lesions in the lumbar spine on CT scan. Isotope bone scan
revealed areas of increased uptake consistent with metastatic disease.
The patient received chemotherapy with significant reduction in the
para-aortic node mass and then radiotherapy to that region. Serial
Ct scans over 8 months since irradiation have shown continued
shrinkage of dense residual retroperitoneal tissue but no significant
change in the lumbar lytic lesions. Five months after completion of
all treatment, the patient complained of acute low back pain after
coughing and partial collapse of the fourth lumbar vertebra was
noted on plain radiographs. The symptoms resolved over 6 to 8
weeks with supportive treatment.
A twelfth patient, not described so far, also developed a
destructive bony lesion in the lumbar spine. He had completed
POMB/ACE for a bulky para-aortic and mediastinal metastatic
MTI 3 1/2 years previously and presented with back pain and loss
of Dl1-12 intervertebral disc space with bony erosion of Dl 1
vertebra together with an adjacent soft tissue mass. The loss of the
intervertebral disc suggested infective aetiology and needle biopsy of
the affected area revealed chronic inflammation although a positive
culture was never obtained. The patient was treated for an atypical
tuberculous infection and was treated with appropriate chemo-
therapy for 12 months and immobilisation. He is now fully mobile
nearly two years after completing his antituberculous therapy.
Discussion
2-57 14-61 These data suggest clinically detectable bone involvement
occurs in 3% of patients presenting with metastatic GCT
2 24 (10%) (95% confidence limits: +1%; +6%). Incidence appeared
3 119 (49%) higher among patients relapsing after previous therapy (9%)
1 62 (25%) but it was not possible to show a statistical difference (95%
1 23 (9%) confidence limits: -2%, + 14%). Most of our patients in our
0 8 (3%) series has non-seminomatous GCT so, while our data should
0 8 reflect incidence of bone metastases in this group accurately,
they may be less representative of the seminoma population.
7 216 (89%) None of our affected patients had extragonadal GCT but
0 28 (11%) bone metastases from such tumours are described elsewhere
(Gay et al., 1985; Martini et al., 1974; Richardson et al.,
6 232 (95%) 1981). Among 58 patients treated for ovarian GCT at this
3 77 (32%) institution over a similar period, no bone involvement was
0 26 (11%) seen. Bones of the trunk, especially lumbar spine, were most
2 23 (9%) commonly affected by metastatic GCT, in accord with
0 9 (4%) historical autopsy series (Dixon & Moore, 1953; Mostofi,
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Figure 1 CT images (a & b) and myelogram films (c) from Case
I showing a very large para-aortic lymph node mass with bone
destruction of the third lumbar vertebra which onset after
commencement of chemotherapy and caused spinal cord com-
pression (myelography dye was introduced from above to show
the level).
Figure 2 (a) Sagittal MR image of Case II, who presented with
paraplegia, showing bone destruction and cord compression by
tumour mass involving second lumbar vertebra plus para-aortic
lymphadenopathy (maximum diameter 2-3cm) at a lower level
(see arrow). Repeat scan (b) was obtained after normalization of
tumour markers with chemotherapy.
1973). Longstanding associated radiographic changes reflect
the slow rate of bone healing and some of these abnormali-
ties may be permanent.
Survival among our patients presenting with bone disease,
was similar to the whole group and appeared better than in
those with liver or CNS metastases at presentation. These
data suggest osseus metastases may not confer such an
adverse prognosis as is commonly believed (Bosl et al., 1986;
Einhorn et al., 1985; Logothetis et al., 1986; Williams et al.,
1987; Bajorin et al., 1988).
Unfortunately, not all cases of bony involvement described
were confirmed histologically. Bone biopsy was undertaken
only after careful consideration of potential management
implications in each case or if other surgical intervention was
necessary. Blood supply to lumbar vertebra may well be
compromised by bulky retroperitoneal lymphadenopathy and
lead to bone infarction. The possibility that ischaemic necro-
sis may be the underlying pathology of the collapse of
vertebra in some of these patients is the reason we have
referred to bone disease in these patients where true bone
metastases may not always be present. CT or isotope bone
scanning will not distinguish metastatic tumour from bone
infarction. However, bone scan abnormalities in all our
patients with very bulky retroperitoneal disease did show
several 'hot spots' including some in vertebrae not immedia-
tely adjacent to the para-aortic node masses, more suggestive796 R.N. HITCHINS et al.
of metastatic disease. Even if some of the lumbar vertebral
abnormalities observed were due to infarction, their causa-
tion remains intimately disease-related if due to vascular
compression by adjacent retroperitoneal tumour.
Back pain is a well described presenting complaint in
metastatic GCT (Cantwell et al., 1987), usually due to para-
aortic lymph node enlargement. Even though bone disease is
rare, our patient with paraplegia from lumbar spine metas-
tases, but with minimal associated retroperitoneal lymph-
adenopathy, illustrates the importance of considering osseus
involvement, especially if bony tenderness is present. As
most patients with GCT are young, even minor abnor-
malities on plain radiographs must be regarded as suspi-
cious. Because GCT are so sensitive to cisplatin-based
chemotherapy, rapid tumour lysis may lead to progressive
bone destruction after initiation of treatment as illustrated
by our patient with lumbar vertebral collapse in such
circumstances. Patients with large areas of bone destruction
need careful management after commencing chemotherapy
to prevent spinal cord compression developing. Even after
successful completion of therapy, slow bone healing may
result in a persisting tendency to easy fracture as in our
patient with crush fracture after coughing several months
post-treatment.
Although bone disease seemed more frequent among
relapsed GCT patients, it was still uncommon and we did
not see isolated bone relapse. Histologic confirmation should
be obtained before ascribing solitary osseus lesions to relapse
in patients previously treated for GCT as illustrated by our
patient with mycobacterial bone disease.
This work was supported by the Cancer Research Campaign.
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